Data protection Impressum

R&D

AC Immune’s ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

AC Immune receives FDA Fast Track designation for Alzheimer’s disease therapy

6 August 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (June 2024)

26 June 2024

Three heritage buildings in Neuchâtel are nearing completion with 33,300 solar tiles from CSEM and Freesuns, marking significant progress in the 2050 energy transition.

Neuchâtel equips heritage buildings with innovative solar roof tiles

25 June 2024

Switzerland ranks as the second most competitive country in the 2024 IMD World Competitiveness Ranking, demonstrating significant improvements in economic performance and business efficiency.

Switzerland secures second spot in IMD’s 2024 World Competitiveness Ranking

19 June 2024

Researchers at EPFL have introduced ChemCrow, a revolutionary AI system that integrates 18 advanced tools, significantly enhancing efficiency in chemical research.

EPFL scientists unveil a groundbreaking AI for chemical synthesis

22 May 2024

An EPFL research project has developed a method based on machine learning to quickly and accurately search large databases, leading to the discovery of 14 new materials for solar cells.

EPFL uses machine learning to discover new solar-cell materials

21 May 2024

Takeda will receive an exclusive option to license AC Immune's ACI-24.060, a breakthrough therapy to combat the progression of Alzheimer's disease, for an upfront payment of USD 100 million and potential milestone payments of USD 2.1 billion.

AC Immune and Takeda sign USD 100 million deal to treat Alzheimer’s disease

13 May 2024

Risklick, a spin-off from the University of Bern, has unveiled its cutting-edge software, Protocol AI, designed to transform the landscape of pharmaceutical development.

UniBe spin-off Risklick unveils AI tool to streamline clinical trials

29 April 2024

Researchers at the EPFL have engineered lab-grown mini-colons that replicate the development of colorectal tumors with high fidelity.

EPFL scientists create lab-grown mini-colons to advance colorectal cancer research

29 April 2024

The latest edition of the Swiss Biotech Report underscores the continued growth and resilience of Switzerland’s biotech sector, attributing success to strong international collaborations and innovative advancements that promise to reshape healthcare worldwide.

The Swiss biotech industry: reliable partners beyond borders

23 April 2024

1 2 3 4 5 6 7 8 9 … 14